Sign up to access all valuation multiples
Selcuk Ecza Deposu Ticaret ve Sanayi AS and its subsidiaries are in the business of export and import of drugs and patent medicines, medical supplies with pharmacy depot operations and also organize distribution channels between drug manufacturers, hospitals, and pharmacies. The company also distributes cosmetics, personal care, infant food, vitamins, medical and similar products.
1970
6.5K+
LTM Revenue $3.8B
LTM EBITDA $134M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Selcuk Ecza Deposu has a last 12-month revenue (LTM) of $3.8B and a last 12-month EBITDA of $134M.
In the most recent fiscal year, Selcuk Ecza Deposu achieved revenue of $3.1B and an EBITDA of $153M.
Selcuk Ecza Deposu expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Selcuk Ecza Deposu valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.8B | XXX | $3.1B | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $317M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 10% | XXX | XXX | XXX |
| EBITDA | $134M | XXX | $153M | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 5% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $131M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 4% | XXX | XXX | XXX |
| Net Profit | $28.4M | XXX | $50.2M | XXX | XXX | XXX |
| Net Margin | 1% | XXX | 2% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $117M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, Selcuk Ecza Deposu's stock price is TRY 87 (or $2).
Selcuk Ecza Deposu has current market cap of TRY 54.3B (or $1.3B), and EV of TRY 47.7B (or $1.2B).
See Selcuk Ecza Deposu trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.3B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, Selcuk Ecza Deposu has market cap of $1.3B and EV of $1.2B.
Selcuk Ecza Deposu's trades at 0.4x EV/Revenue multiple, and 7.6x EV/EBITDA.
Equity research analysts estimate Selcuk Ecza Deposu's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Selcuk Ecza Deposu has a P/E ratio of 46.6x.
See valuation multiples for Selcuk Ecza Deposu and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 0.3x | XXX | 0.4x | XXX | XXX | XXX |
| EV/EBITDA | 8.7x | XXX | 7.6x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 8.9x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 46.6x | XXX | 26.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSelcuk Ecza Deposu's last 12 month revenue growth is 21%
Selcuk Ecza Deposu's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $29K for the same period.
Selcuk Ecza Deposu's rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Selcuk Ecza Deposu's rule of X is 57% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Selcuk Ecza Deposu and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 21% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Growth | 23% | XXX | 52% | XXX | XXX | XXX |
| Rule of 40 | 24% | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 57% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $29K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Sigma Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| MedPlus India | XXX | XXX | XXX | XXX | XXX | XXX |
| SC Ropharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Profarma Distribuidora | XXX | XXX | XXX | XXX | XXX | XXX |
| Pague Menos | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Selcuk Ecza Deposu acquired XXX companies to date.
Last acquisition by Selcuk Ecza Deposu was XXXXXXXX, XXXXX XXXXX XXXXXX . Selcuk Ecza Deposu acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Selcuk Ecza Deposu founded? | Selcuk Ecza Deposu was founded in 1970. |
| Where is Selcuk Ecza Deposu headquartered? | Selcuk Ecza Deposu is headquartered in Turkey. |
| How many employees does Selcuk Ecza Deposu have? | As of today, Selcuk Ecza Deposu has 6.5K+ employees. |
| Is Selcuk Ecza Deposu publicy listed? | Yes, Selcuk Ecza Deposu is a public company listed on IST. |
| What is the stock symbol of Selcuk Ecza Deposu? | Selcuk Ecza Deposu trades under SELEC ticker. |
| When did Selcuk Ecza Deposu go public? | Selcuk Ecza Deposu went public in 2006. |
| Who are competitors of Selcuk Ecza Deposu? | Similar companies to Selcuk Ecza Deposu include e.g. Sigma Healthcare, MedPlus India, SC Ropharma, Profarma Distribuidora. |
| What is the current market cap of Selcuk Ecza Deposu? | Selcuk Ecza Deposu's current market cap is $1.3B |
| What is the current revenue of Selcuk Ecza Deposu? | Selcuk Ecza Deposu's last 12 months revenue is $3.8B. |
| What is the current revenue growth of Selcuk Ecza Deposu? | Selcuk Ecza Deposu revenue growth (NTM/LTM) is 21%. |
| What is the current EV/Revenue multiple of Selcuk Ecza Deposu? | Current revenue multiple of Selcuk Ecza Deposu is 0.3x. |
| Is Selcuk Ecza Deposu profitable? | Yes, Selcuk Ecza Deposu is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Selcuk Ecza Deposu? | Selcuk Ecza Deposu's last 12 months EBITDA is $134M. |
| What is Selcuk Ecza Deposu's EBITDA margin? | Selcuk Ecza Deposu's last 12 months EBITDA margin is 4%. |
| What is the current EV/EBITDA multiple of Selcuk Ecza Deposu? | Current EBITDA multiple of Selcuk Ecza Deposu is 8.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
